ThinkCyte's VisionSort technology integrates traditional fluorescence flow cytometry with advanced high-dimensional morphological profiling and artificial intelligence (AI) to facilitate label-free cell sorting and unbiased single-cell profiling. This innovative approach allows for the identification and selection of therapeutically relevant cells in various applications, including cell therapy research and development, drug discovery, and disease profiling. By enabling faster and more cost-effective alternatives to conventional plate-based phenotypic screening, VisionSort enhances the ability to screen a broader range of phenotypes, making it compatible with both small molecule and CRISPR-based methodologies.

Additionally, VisionSort excels in morphology-based cell sorting, achieving record high-throughput rates through the integration of ultrafast cell profiling techniques. This capability allows researchers to characterize and sort cells based on subtle morphological differences, which is crucial for identifying disease-relevant phenotypes and novel biomarkers. The technology supports diverse screening workflows and requires minimal cell quantities, thereby streamlining the drug discovery process and linking genotypes to phenotypes efficiently. Overall, ThinkCyte's VisionSort represents a significant advancement in the field of cellular analysis and therapeutic development.

United States

ThinkCyte's mission is to provide scientists and biomedical professionals with a transformational single-cell technology that accelerates biological discoveries and enable the development of novel treatments and diagnostics through the integration of advanced hardware, machine learning, and biotechnology.

ThinkCyte

Company Details